Home » Stocks » Retrophin

Retrophin, Inc. (RTRX)

Stock Price: $19.22 USD 0.11 (0.55%)
Updated Aug 7, 2020 1:39 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 829.23M
Revenue (ttm) 187.26M
Net Income (ttm) -92.01M
Shares Out 50.91M
EPS (ttm) -2.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $19.22
Previous Close $19.11
Change ($) 0.11
Change (%) 0.55%
Day's Open 19.14
Day's Range 18.99 - 19.90
Day's Volume 91,338
52-Week Range 8.98 - 21.92

More Stats

Market Cap 829.23M
Enterprise Value 581.87M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 50.91M
Float 43.29M
EPS (basic) -2.11
EPS (diluted) -2.12
FCF / Share -1.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.90M
Short Ratio 8.23
Short % of Float 10.32%
Beta 0.83
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.43
PB Ratio 3.09
Revenue 187.26M
Operating Income -74.89M
Net Income -92.01M
Free Cash Flow -56.10M
Net Cash 247.37M
Net Cash / Share 5.73
Gross Margin 90.84%
Operating Margin -39.99%
Profit Margin -49.10%
FCF Margin -29.96%
ROA -7.06%
ROE -30.89%
ROIC -19.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$29.43*
(53.16% upside)
Low
21.0
Current: $19.22
High
38.0
Target: 29.43
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue17516415513499.8928.20--
Revenue Growth6.75%6.01%15.98%33.74%254.19%---
Gross Profit17015915112997.7127.63--
Operating Income-107-68.45-34.40-39.83-36.97-79.81-24.77-30.26
Net Income-146-103-59.73-47.90117-111-34.63-30.34
Shares Outstanding42.3440.4338.7737.0033.5625.0614.213.66
Earnings Per Share-3.46-2.54-1.54-1.293.17-4.43-2.44-8.29
Operating Cash Flow-58.21-24.967.40-3.44-1.39-45.85-17.59-2.74
Capital Expenditures-0.20-0.73-0.89-1.43-0.02-0.66-0.12-0.02
Free Cash Flow-58.41-25.696.52-4.87-1.41-46.51-17.71-2.76
Cash & Equivalents39947230130327627.766.170.01
Total Debt20521845.0844.4243.7783.771.460.88
Net Cash / Debt194254256258233-56.014.71-0.87
Assets60570952052551213520.502.39
Liabilities38439122721821217340.175.80
Book Value221318293308300-37.25-19.67-3.41
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Retrophin, Inc.
Country United States
Employees 221
CEO Eric Dube

Stock Information

Ticker Symbol RTRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RTRX

Description

Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.